1 优秀医疗投资者电话会议 2022年10月26日 2022年第三季度业绩 弗雷德·兰普普洛斯 董事长兼首席执行官 劳尔·帕拉 首席财务官

2与历史事实陈述不同的前瞻性STATEMENTS Thispresentationandanyaccompanyingmanagementcommentaryinclude“forward-lookingstatements，”asdefinedwithinapplicablesecuritieslawsandregulations.Allstatementsinthis presentation，警示陈述是“前瞻性陈述”，包括但不限于有关业绩预测计划、净销售额、净收益(公认会计原则和非公认会计原则)、营业收入和利润率(公认会计原则和非公认会计原则)、毛利和利润率(公认会计原则和非公认会计原则)、毛利和利润率(公认会计原则和非公认会计原则)、盈利(公认会计原则和非公认会计原则)、自由现金流量、财务 措施、futuregrowthandprofitexpectationsorforecastedeconomicconditions，或通过Merit’sFoundationsforGrowthProgramorother expensereductioninitiatives，orthedevelopmentorcommercializationofnewproducts，areforward-lookingstatementswithinthemeaningofSection27AoftheSecuritiesActof1933，实现和实现的财务 措施、经修订的andSection21EoftheSecuritiesExchangeActof1934，、andaresubjecttorisksanduncertaintiessuchasthosedescribedinMerit’sAnnualReportonForm10-Kforthe yearendedDecember31，。2021(the“2021AnnualReport”)andotherfilingswiththeSEC.SuchrisksanduncertaintiesincludeinherentrisksanduncertaintiesrelatingtoMerit’sinternalmodelsor theprojectionsinthisrelease；价值供应链中的中断、manufacturingorsterilizationprocesses；reducedavailabilityof，和与commoditycomponents； adversechangesinfreight，shippingandtransportationexpenses；risksrelatingtoMerit’spotentialinabilitytosuccessfullymanagegrowththroughacquisitionsgenerally，includingtheinabilityto effectivelyintegrateacquiredoperationsorproductsorcommercializetechnologydevelopedinternallyoracquiredthroughcompleted，proposedorfuturetransactions；negativechangesin economicandindustryconditionsintheUnitedStatesorothercountries相关的价格增加, Includinginflation；fluctuationsininterestorforeigncurrencyexchangerates；risksanduncertaintiesassociatedwith Merit’sinformationtechnologysystems，includingthepotentialforbreachesofsecurityandevolvingregulationsregardingprivacyanddataprotection；governmentalscrutinyandregulationofthe medicaldeviceindustry，包括政府查询、investigationsandproceedingsinvolvingMerit；litigationandotherjudicialproceedingsaffectingMerit；restrictionsonMerit’sliquidityor businessoperationsresultingfromitsdebtagreements；infringementofMerit’stechnologyortheassertionthatMerit’stechnologyinfringestherightsofotherparties；productrecallsandproduct liabilityclaims；changesincustomerpurchasingpatternsorthemixofproductsMeritsells；difficulties，延迟和与开发相关的支出，testingandregulatoryapprovalor clearanceofMerit’sproducts，includingthepursuitofapprovalsundertheE.U.MedicalDeviceRegulation，andrisksthatsuchproductsmaynotbedevelopedsuccessfullyorapprovedfor commercialuse；thepotentialoffines，penaltiesorotheradverseconsequencesifMerit’semployeesoragentsviolatetheU.S.ForeignCorruptPracticesActorotherlawsorregulations；lawsand regulationstargetingfraudandabuseinthehealthcareindustry；potentialforsignificantadversechangesingoverningregulations，includingreformstotheproceduresforapprovalorclearanceof Merit’sproductsbytheU.S.Food&DrugAdministrationorcomparableregulatoryauthoritiesinotherjurisdictions；changesintaxlawsandregulationsintheUnitedStatesorothercountries； terminationofrelationshipswithMerit’ssuppliers, Orfailureofsuchsupplierstoperform；risksanduncertaintiesassociatedwiththeCOVID-19pandemicandMerit’sresponsethereto； concentrationofasubstantialportionofMerit’srevenuesamongafewproductsandprocedures；developmentofnewproductsandtechnologythatcouldrenderMerit’sexistingorfuture productsobsolete；marketacceptanceofnewproducts；volatilityinthemarketpriceofMerit’scommonstock；modificationorlimitationofgovernmentalorprivateinsurancereimbursement policies；changesinhealthcarepoliciesormarketsrelatedtohealthcarereforminitiatives；failuretocomplywithapplicableenvironmentallaws；changesinkeypersonnel；workstoppageor transportationrisks；failuretointroduceproductsinatimelyfashion；priceandproductcompetition；availabilityoflaborandmaterials；fluctuationsinandobsolescenceofinventory；andother factorsreferencedinthe2021AnnualReportandothermaterialsfiledwiththeSEC. Allsubsequentforward-lookingstatementsattributabletoMeritorpersonsactingonitsbehalfareexpresslyqualifiedintheirentiretybythesecautionarystatements.Actualresultswilllikely differ，和可能在实质上不同，fromanticipatedresults.Financialestimatesaresubjecttochangeandarenotintendedtoberelieduponaspredictionsoffutureoperatingresults.Those estimatesandallotherforward-lookingstatementsincludedinthisdocumentaremadeonlyasofthedateofthisdocument，和其他适用法律所要求的其他概念，Meritassumesno obligationtoupdateordiscloserevisionstoestimatesandallotherforward-lookingstatements. 2

因此，3 NON-GAAPFINANCIALMEASURES AlthoughMerit’sfinancialstatementsarepreparedinaccordancewithaccountingprinciplesgenerallyacceptedintheUnitedStatesof America(“GAAP”)，Merit’smanagementbelievesthatcertainnon-GAAPfinancialmeasuresprovideinvestorswithusefulinformation regardingtheunderlyingbusinesstrendsandperformanceofMerit’songoingoperationsandcanbeusefulforperiod-over-period comparisonsofsuchoperations.Certainfinancialmeasuresincludedinthispresentation，orwhichmaybereferencedin management’sdiscussionofMerit’shistoricalandfutureoperationsandfinancialresults，havenotbeencalculatedinaccordancewith GAAP，和arereferencedasnon-GAAPfinancialmeasures.Readersshouldconsidernon-GAAPmeasuresusedinthis presentationinadditionto，不是financialreportingmeasurespreparedinaccordancewithGAAP.Thesenon-GAAP financialmeasuresgenerallyexcludesome，的替代品，而不是itemsthatmayaffectMerit‘snetincome.Inaddition，theyaresubjectto inherentlimitationsastheyreflecttheexerciseofjudgmentbymanagementaboutwhichitemsareexcluded.Additionally，non-GAAP financialmeasuresusedinthispresentationmaynotbecomparablewithsimilarlytitledmeasuresofothercompanies.Meriturges readerstoreviewthereconciliationsofitsnon-GAAPfinancialmeasurestothecomparableGAAPfinancialmeasures，Andnottorely onanysinglefinancialmeasuretoevaluateMerit’sbusinessorresultsofoperations.Pleasereferto“NotestoNon-GAAPFinancial Measures”attheendofthesematerialsformoreinformation. TRADEMARKS Unlessnotedotherwise，trademarksusedinthispresentationarethepropertyofMeritMedicalSystems，Inc.，intheUnitedStatesand otherjurisdictions. 3

4 第三季度2022Q3 2021YTD 2022YTD 2021 Revenue $287.2M$267.0M$857.6M$796.3M Gross利润率 44.8%45.1%44.8%44.8% 营业利润率 6.5%6.0%6.7%4.9% 每Income $15.3M$12.0M$41.1M$27.8M Earnings净Share $0.27$0.21$0.71$0.49 FinancialSummary GAAP 4

5 第三季度2022Q3 2021YTD 2022YTD 2021 收入 (不变货币，Organic) † $295.2M$267.0M$873.3M$796.3M Gross利润率 48.4%49.1%48.5%49.0% 营业利润率 16.1%14.8%16.7%15.6% 每Income $37.0M$30.2M$109.7M$95.4M Earnings净Share $0.64$0.52$1.91$1.67 FinancialSummary Non-GAAP* 5 *有关本演示文稿中使用的非公认会计准则计量的其他信息，请参阅下面的“非公认会计准则财务计量说明”。 † 非公认会计准则财务计量，代表不变的货币收入，有机。

6 收入明细-第三季度 区域第三季度2022Q3 2021$Change%ChangeCC%Change* U.S. $164,571$151,505$13,0668.6%6.6% APAC60,17556,9503,2255.7%13.7% EMEA52,06049,7332,3274.7%17.3% Rest of World10,3698,8331,53617.4%18.8% Total International 122,604115,5167,088 6.1%15.6% Total $287,175$267,021$20,1547.5%10.5% 6 *非公认会计准则财务指标，指按不变货币(“CC”)计算的收入增长。有关本演示文稿中使用的非GAAP衡量标准的其他信息，请参阅下面的“非GAAP财务衡量标准附注”。 单位为千，百分比除外

7 收入明细-YTD 区域YTD 2022YTD 2021$Change%ChangeCC%Change* U.S. $482,237$451,648$30,5896.8%5.4% APAC182,656169,61813,0387.7%12.3% EMEA160,743152,0688,6755.7%15.0% Rest of World31,93022,9259,00539.3%38.6% Total International 375,329344,61130,718 8.9%15.2% Total $857,566$796,259$61,3077.7%9.7% 7 *非公认会计准则财务指标，指按不变货币(“CC”)计算的收入增长。有关本演示文稿中使用的非GAAP衡量标准的其他信息，请参阅下面的“非GAAP财务衡量标准附注”。 单位为千，百分比除外

8 财务指标 指标第三季度2022Q3 2021YTD 2022YTD 2021 折旧和摊销$20.4M$208M$6130万$6320万 股票补偿(基于业绩)1.4M1.6M4.4M4.0M 股票补偿(非performance-based)3.2M3.2M9.3M7.6M Operating现金流量35.5M25.0M86.3M101.4M 资本支出-财产和设备15.8M6.8M32.5M19.6M 8

9 *有关本演示文稿中使用的非公认会计准则财务指标的更多信息，请参阅下面的“非公认会计准则财务指标说明”。 截至2022年12月31日的年度，Merit的财务指导会受到本演示文稿以及Merit提交给美国证券交易委员会(“美国证券交易委员会”)的文件中确定的风险和不确定性的影响。请参阅“有关前瞻性陈述的警示声明。” 财务指标修订指南先前指引 净销售额11.45亿至11.151亿美元 11.23亿至11.35亿美元 净收益6,480万至6,830万美元6,240万至6,830万美元 每股收益 (GAAP) 1.13至1.19美元1.08至1.18美元 净收益 (非GAAP)* 146美元90万美元至1.504亿美元1.396亿美元至1.455亿美元 每股收益 (非公认会计准则)* 2.55美元至2.61美元2.42美元至2.52美元 更新后的2022年财务指引

10 附录 10

11 NotestoNon-GAAPFinancialMeasures Foradditionaldetails，pleaseseetheaccompanyingpressreleaseandforward-lookingstatementdisclosure. ThesepresentationmaterialsandassociatedcommentaryfromMerit’smanagement，以及今天发布的新闻稿，使用非GAAP财务指标，including： •constantcurrencyrevenue； •constantcurrencyrevenue，organic； •non-GAAPgrossprofitandmargin； •non-GAAPoperatingincomeandmargin； •non-GAAPnetincome； •non-GAAPearningspershare；And •freecashflow. Merit’smanagementteamusesthesenon-GAAPfinancialmeasurestoevaluateMerit’sprofitabilityandefficiency，tocompareoperatingandfinancialresultstopriorperiods，to evaluatechangesintheresultsofitsoperatingsegments，andtomeasureandallocatefinancialresourcesinternally.However，Merit’smanagementdoesnotconsidersuchnon- GAAPmeasuresinisolationorasanalternativetomeasuresdeterminedinaccordancewithGAAP. Readersshouldconsidernon-GAAPmeasuresusedinthispresentationinadditionto，不是financialreportingmeasurespreparedinaccordancewithGAAP.These non-GAAPfinancialmeasuresgenerallyexcludesome，的替代品，但不是所有的，itemsthatmayaffectMerit’snetincome.Inaddition，theyaresubjecttoinherentlimitationsastheyreflectthe exerciseofjudgmentbymanagementaboutwhichitemsareexcluded.Meritbelievesitisusefultoexcludesuchitemsinthecalculationofnon-GAAPearningspershare，非GAAP总收入和利润，非GAAP运营收入和利润，以及非GAAP净收入(每个案例，asfurtherillustratedinthereconciliationtablesbelow)because suchamountsinanyspecificperiodmaynotdirectlycorrelatetotheunderlyingperformanceofMerit’sbusinessoperationsandcanvarysignificantlybetweenperiodsasaresult offactorssuchasacquisitionorotherextraordinarytransactions，non-cashexpensesrelatedtoamortizationorwrite-offofpreviouslyacquiredtangibleandintangibleassets， 支出, Expensesresultingfromnon-ordinarycourselitigationoradministrativeproceedingsandresultingsettlements，公司转换费用， governmentalproceedingsorchangesintaxorindustryregulations，在处置某些资产上的损失，anddebtissuancecosts.Meritmayincursimilartypesofexpenses inthefuture，andthenon-GAAPfinancialinformationincludedinthispresentationshouldnotbeviewedasastatementorindicationthatthesetypesofexpenseswillnotrecur. Additionally，thenon-GAAPfinancialmeasuresusedinthispresentationmaynotbecomparablewithsimilarlytitledmeasuresofothercompanies.Meriturgesinvestorsand potentialinvestorstoreviewthereconciliationsofitsnon-GAAPfinancialmeasurestothecomparableGAAPfinancialmeasures，andnottorelyonanysinglefinancialmeasureto evaluateMerit’sbusinessorresultsofoperations.

12 NotestoNon-GAAPFinancialMeasures(cont.) ConstantCurrencyRevenue Merit’sconstantcurrencyrevenueispreparedbyconvertingthecurrent-periodreportedrevenueofsubsidiarieswhosefunctionalcurrencyisacurrencyotherthantheU.S.dollarat theapplicableforeignexchangeratesineffectduringthecomparableprior-yearperiod，andadjustingfortheeffectsofhedgingtransactionsonreportedrevenue，whicharerecorded intheU.S.Theconstantcurrencyrevenueadjustmentsof$8.0millionand$15.8milliontoreportedrevenueforthethreeandnine-monthperiodsendedSeptember30,2022，were calculatedusingtheapplicableaverageforeignexchangeratesforthethreeandnine-monthperiodsendedSeptember30,2021。 恒定当前收入，有机 固定现货收入，有机，定义，按优先或财政期间，asGAAPrevenue.Withrespecttocurrentfiscalyearperiods，恒定货币收入，有机，isdefinedasconstantcurrencyrevenue(asdefinedabove)，lessrevenuefromcertainacquisitions.Forthethreeandnine-monthperiodsendedSeptember30,2022， therewerenorevenuesfromacquisitionsexcludedinthecalculationofMerit’sconstantcurrencyrevenue，Organic. Non-GAAPGrossProfitandMargin Non-GAAPgrossprofitiscalculatedbyreducingGAAPcostofsalesbyamountsrecordedforamortizationofintangibleassetsandcertaininventorywrite-offs.Non-GAAPgross marginiscalculatedbydividingnon-GAAPgrossprofitbyreportednetsales. Non-GAAPOperatingIncomeandMargin Non-GAAPoperatingincomeiscalculatedbyadjustingGAAPoperatingincomeforcertainitemswhicharedeemedbyMerit’smanagementtobeoutsideofcoreoperationsand varyinamountandfrequencyamongperiods，suchasexpensesrelatedtoacquisitionsorotherextraordinarytransactions，non-cashexpensesrelatedtoamortizationorwrite-offof previouslyacquiredtangibleandintangibleassets，确定的费用、基于业绩的股票薪酬费用、公司转换费用, Expenses resultingfromnon-ordinarycourselitigationoradministrativeproceedingsandresultingsettlements，governmentalproceedingsorchangesinindustryregulations，aswellasother itemsreferencedinthetablesbelow.Non-GAAPoperatingmarginiscalculatedbydividingnon-GAAPoperatingincomebyreportednetsales.

13 NotestoNon-GAAPFinancialMeasures(cont.) Non-GAAPNetIncome Non-GAAPnetincomeiscalculatedbyadjustingGAAPnetincomefortheitemssetforthinthedefinitionofnon-GAAPoperatingincomeabove，aswellasforexpensesrelatedto debtissuancecosts，因处置某些资产而亏损，税制变更，分别aswellasotheritemssetforthinthetablesbelow. Non-GAAPEPS Non-GAAPEPSisdefinedasnon-GAAPnetincomedividedbythedilutedsharesoutstandingforthecorrespondingperiod. FreeCashFlow FreecashflowisdefinedascashflowfromoperationscalculatedinaccordancewithGAAP，lesscapitalexpendituresforpropertyandequipmentcalculatedinaccordancewith GAAP，assetforthintheconsolidatedstatementofcashflows. OtherNon-GAAPFinancialMeasureReconciliation Thefollowingtablessetforthsupplementalfinancialdataandcorrespondingreconciliationsofnon-GAAPfinancialmeasurestoMerit’scorrespondingfinancialmeasuresprepared inaccordancewithGAAP，个别，forthethreeandnine-monthperiodsendedSeptember30,2022and2021.Thenon-GAAPincomeadjustmentsreferencedinthefollowing tablesdonotreflectnon-performance-basedstockcompensationexpenseof$3.2millionand$3.2millionforthethree-monthperiodsendedSeptember30,2022and2021， ，and$9.3millionand$7.6millionforthenine-monthperiodsendedSeptember30,2022and2021，。

14 ReconciliationofGAAPNetIncometoNon-GAAPNetIncome (Unaudited;inthousandsexceptpershareamounts) Note: Certain per share impacts may not sum to totals due to rounding. GAAP net income$17,602 $(2,330) $15,272 $0.27 $14,177 $(2,210) $11,967 $0.21 Non-GAAP adjustments: Cost of Sales Amortization of intangibles 10,487 (2,571) 7,916 0.14 10,573 (2,626) 7,947 0.14 Operating Expenses Contingent consideration expense 915 — 915 0.02 1,115 (16) 1,099 0.02 Amortization of intangibles 1,554 (384) 1,170 0.02 1,793 (449) 1,344 0.02 Performance-based share-based compensation (b) 1,353 (70) 1,283 0.02 1,639 (207) 1,432 0.02 Corporate transformation and restructuring (c) 8,535 (1,796) 6,739 0.12 4,282 (1,061) 3,221 0.06 Acquisition-related667 (163) 504 0.01 2,866 (711) 2,155 0.04 Medical Device Regulation expenses (d) 3,873 (948) 2,925 0.05 1,129 (280) 849 0.01 Other (e) 116 (28) 88 0.00 159 (78) 81 0.00 Other (Income) Expense Amortization of long-term debt issuance costs 151 (37) 114 0.00 151 (37) 114 0.00 Loss on disposal of business unit135 (32) 103 0.00 — — — — Non-GAAP net income $45,388 $(8,359) $37,029 $0.64 $37,884 $(7,675) $30,209 $0.52 Diluted shares 57,586 57,549 Reconciliation of GAAP Net Income to Non-GAAP Net Income (Unaudited, in thousands except per share amounts) Three Months Ended Three Months Ended September 30, 2022September 30, 2021 After-TaxPer Share Impact Pre-TaxTax ImpactAfter-TaxPer Share ImpactPre-TaxTax Impact

15 ReconciliationofGAAPNetIncometoNon-GAAPNetIncome (Unaudited；(以千股为单位) 注意：由于四舍五入的原因，某些每股影响的总和可能不是总计。 GAAP净收入 $ 52,474 $ (11,359) $ 41,115 $ 0.71 $ 33,736 $ (5，895) $ 27，$ $ 0.49 非公认会计准则adjustments： Cost of Sales {br 无形资产摊销 31，539 (7,733) 23,806 0.41 31,884 (7,918) 23，966 0.42 库存核销(a) — — — — 1,620 (202) 1.418 0.02 运营Expenses Contingent对价费用 4,702 (17) 4,685 0.08 3，322 (2) 3,320 0.06 减值费用 1,672 (318) 1,354 0.02 4，283 (481) 3,802 0.07 无形资产摊销 4,749 (1,176) 3,573 0.06 5,397 (1，045 0.07 Performance-based股票薪酬(B) 4,354 (413) 3,941 0.07 3,998 (494) 3，504 0.06 企业转型重组(C) 20,432 (4,702) 15,730 0.27 17,044 (4,223) 12，821 0.22 Acquisition-related 1, 901 (465) 1,436 0.02 8,475 (2,101) 6,374 0.11 医疗器械规费(D) 8,451 (2，069) 6,382 0.11 2,523 (625) 1,898 0.03 其他(E) 7,845 (1,863) 5，982 0.10 6,534 (468) 6，066 0.11 其他(收入)支出 长期债务发行costs 453 (111) 342 0.01 453 (112) 341摊销 0.01 业务部门处置亏损 1，390 (32) 1,358 0.02 — — — — Non-GAAP净收入 $139,962 $(30,258) $109，704 $1.91 $119,269 $(23,873) $95,396 $1.67 稀释股份 57,573 57，274 每股税后影响 税前 每股税后影响 税前 每股税后影响 截至9个月 截至2021年9月30日的9个月 2021年9月30日

16 ReconciliationofGAAPOperatingIncometoNon-GAAPOperatingIncome (Unaudited;inthousandsexceptpercentages) Note: Certain percentages may not sum to totals due to rounding. Net Sales as Reported $287,175 $267,021 $857,566 $796,259 GAAP Operating Income 18,657 6.5 %15,931 6.0 %57,146 6.7 %39,020 4.9 % Cost of Sales Amortization of intangibles 10,487 3.7 %10,573 4.0 %31,539 3.7 %31,884 4.0 % Inventory write-off (a)— — — — — — 1,620 0.2 % Operating Expenses Contingent consideration expense 915 0.3 %1,115 0.4 %4,702 0.5 %3,322 0.4 % Impairment charges — — — — 1,672 0.2 %4,283 0.5 % Amortization of intangibles 1,554 0.5 %1,793 0.7 %4,749 0.6 %5,397 0.7 % Performance-based share-based compensation (b) 1,353 0.5 %1,639 0.6 %4,354 0.5 %3,998 0.5 % Corporate transformation and restructuring (c) 8,535 3.0 %4,282 1.6 %20,432 2.4 %17,044 2.1 % Acquisition-related667 0.2 %2,866 1.1 %1,901 0.2 %8,475 1.1 % Medical Device Regulation expenses (d) 3,873 1.3 %1,129 0.4 %8,451 1.0 %2,523 0.3 % Other (e)116 0.0 %159 0.1 %7,845 0.9 %6,534 0.8 % Non-GAAP Operating Income $46,157 16.1%$39,487 14.8%$142,791 16.7%$124,100 15.6% Amounts% Sales Amounts% SalesAmounts% SalesAmounts% Sales Three Months Ended Three Months Ended Nine Months Ended Nine Months Ended September 30, 2022September 30, 2021September 30, 2022September 30, 2021

17 Footnotes to Reconciliations of GAAP Net Income to Non-GAAP Net Income and GAAP Operating Income to Non-GAAP Operating Income a)Representsthewrite-offofinventoryrelatedtothedivestitureorexitofcertainbusinessesorproductlines. b)Representsperformance-basedshare-basedcompensationexpense,includingstock-settledandcash-settledawards. c)IncludesconsultingexpensesrelatedtotheFoundationsforGrowthProgramandothertransformationcosts,including severancerelatedtocorporateinitiatives. d)RepresentsincrementalexpensesincurredtocomplywiththeE.U.MedicalDeviceRegulation(“MDR”). e)Thethree-monthperiodendedSeptember30,2022includescoststocomplywithMerit’scorporateintegrityagreementwith theU.S.DepartmentofJustice(the“DOJ”).The2022year-to-dateperiodalsoincludesacquiredin-processresearchand developmentchargesof$6.7millionandlegalcostsassociatedwithashareholderderivativeproceeding.The2021periods includeaccruedcontractterminationcostsof$6.1milliontorenegotiatecertaintermsofanacquisitionagreementandcosts tocomplywithMerit’scorporateintegrityagreementwiththeDOJ.

18 Reconciliation of Reported Revenue to Constant Currency Revenue (Non-GAAP), and Constant Currency Revenue, Organic (Non-GAAP) (Unaudited; in thousands except percentages) (a) A non-GAAP financial measure. For a definition of this and other non-GAAP financial measures, see the section of this presentation entitled “Notes to Non-GAAP Financial Measures.” Three Months Ended Nine Months Ended September 30, September 30, % Change 2022 2021 % Change 2022 2021 Reported Revenue 7.5 % $ 287,175 $ 267,021 7.7 % $ 857,566 $ 796,259 Add: Impact of foreign exchange 7,975 — 15,763 — Constant Currency Revenue (a) 10.5 % $ 295,150 $ 267,021 9.7 % $ 873,329 $ 796,259 Less: Revenue from certain acquisitions — — — — Constant Currency Revenue, Organic (a) 10.5 % $ 295,150 $ 267,021 9.7 % $ 873,329 $ 796,259

19 ReconciliationofGAAPGrossMargintoNon-GAAPGrossMargin (Unaudited;asapercentageofreportedrevenue) Note: Certain percentages may not sum to totals due to rounding. a) Represents the write-off of inventory related to the divestiture or exit of certain businesses or product lines. Three Months Ended Nine Months Ended September 30, September 30, 2022 2021 2022 2021 Reported Gross Margin 44.8 % 45.1 % 44.8 % 44.8 % Add back impact of: Amortization of intangibles 3.7 % 4.0 % 3.7 % 4.0 % Inventory write - off (a) — — % — % 0.2 % Non - GAAP Gross Margin 48.4 % 49.1 % 48.5 % 49.0 %